A Randomized, Placebo Controlled, Double-blind First-in-human Single Ascending Dose Study of LNA043 in Primary Osteoarthritis Patients Scheduled for Total Knee Replacement
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2017
At a glance
- Drugs LNA 043 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 16 Oct 2017 Planned End Date changed from 3 Jan 2018 to 9 Jan 2018.
- 16 Oct 2017 Planned primary completion date changed from 20 Dec 2017 to 26 Dec 2017.
- 25 Sep 2017 Planned number of patients changed from 24 to 28.